Beijing Shadong Biotechnology Co., Ltd.

The primary objective was to evaluate whether CPT combined with thalidomide and dexamethasone (TD regimen) has better efficacy than TD regimen alone in the treatment of patients with relapsed or refractory multiple myeloma, and the primary observation indicator is progression-free survival (PFS). The secondary objective was to evaluate the safety of CPT combined with thalidomide and dexamethasone (TD regimen).